ChromaDex Brings TRU NIAGEN® to SXSW® 2019
March 08 2019 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature its
cellular health product, TRU NIAGEN®, at SXSW®, as it marks the
achievement of attaining over 160 research collaborations around
the world on its patented NIAGEN® (nicotinamide riboside)
ingredient.
"To help SXSW® attendees who need an extra boost in their busy
lives, we'll be providing samples of Tru Niagen and discussing the
science that disrupted the multi-billion-dollar anti-aging category
with the discovery of nicotinamide riboside by Dr. Charles
Brenner," says Frank Jaksch, ChromaDex Co-Founder and Executive
Chairman.
The Tru Niagen team will be onsite at the SXSW® Trade Show
(Booth #149) from March 10-13th to provide samples while supplies
last, as well as to explain the importance of NAD+ and the
scientific evidence behind its clinically-studied ingredient which
increases energy at the cellular level. Consumers, from
professional athletes to health care professionals, report improved
energy, increased feelings of well-being, and newfound
resilience.
“Rarely does an ingredient come to market with this level of
independent, human research validating its safety and efficacy at
boosting cellular health,” says ChromaDex CEO Rob Fried. “As the
world begins to understand the critical role of cellular health in
the aging process, Tru Niagen will be there.”
ChromaDex has been a respected pioneer in the health, wellness,
and nutritional ingredient categories for nearly 20 years. In
2018, the Company launched the TRU NIAGEN® PRO line for health care
practitioners, featuring the highest dose of nicotinamide riboside
available in a single capsule, at 300mg. Additionally, the Company
began selling a customized product for professional sports teams
which maintains NSF International’s Certified for Sport®
Certification.
For additional information on the science supporting Tru Niagen
visit www.truniagen.com.
About TRU NIAGEN®:TRU NIAGEN® is a branded
dietary supplement brought to market by key nicotinamide riboside
innovator and patent holder, ChromaDex. NIAGEN® nicotinamide
riboside (NR), also supplied by ChromaDex, is the sole active
ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate
NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide)
levels, which decline with age. Only NIAGEN® has twice been
successfully reviewed under FDA's new dietary ingredient (“NDI”)
notification program, and has also been successfully notified to
the FDA as generally recognized as safe (“GRAS”).
About ChromaDex:ChromaDex Corp. is a
science-based integrated nutraceutical company devoted to improving
the way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide
riboside, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2018, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Media Contact: Alex Worsham, Director
of Strategic Partnerships 949-648-3775 alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna
Gerber, Senior Director of FP&A and Investor Relations
949-344-3782 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024